Contents 3 min read

Claim and source comparison

Saffron: depression trials, adjunctive crocin and safety data.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

A 2005 pilot trial in 40 adults with mild to moderate depression compared 30 mg/day of saffron stigma extract with 20 mg/day of fluoxetine for 6 weeks. Depression scores did not differ significantly between groups.

The small, single-center trial does not establish equivalent treatment effects or long-term safety.

Source 2 · Abstract read

Systematic review / meta-analysis

The 2013 meta-analysis included 2 placebo-controlled trials and 3 trials comparing saffron with antidepressants. Depression scores fell more with saffron in the placebo comparisons.

There were few trials and short follow-up periods. Two review authors reported consulting ties with a company that developed a product containing saffron.

Source 3 · Full text read

Human randomized controlled trial

In a 2015 pilot trial, 40 people with major depression were randomized to 30 mg/day of crocin or placebo alongside an SSRI. At 4 weeks, self-reported depression scores fell more in the crocin arm.

The short pilot did not study SSRI-related sexual dysfunction. Its findings do not apply to all saffron extracts or establish the long-term safety of drug combinations.

Source 6 · Abstract read

Systematic review / meta-analysis

The 2026 safety review included 102 clinical trials and 1 case report. Digestive symptoms were the most commonly reported adverse effects. Some trials did not report adverse effects.

Supplement safety data during pregnancy and breastfeeding are limited. These studies do not establish safety when combined with antidepressants or blood thinners.

Source 8 · Full text read

Our evidence and source methodology

Saffron Extract: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Saffron?

Saffron (Crocus sativus L.) is a plant species with purple flowers, known for being the most expensive spice per gram in the world. Only the three red-orange stigmas (stalks) of each flower are collected by hand; One kilogram of dried saffron requires approximately 150,000 flowers. Türkiye, especially in Karabük province Safranbolu The city is among the countries that have historical ties with saffron. It has been used in Persian and Indian medicine since ancient times as a mood stabilizer, aphrodisiac and digestive supporter.

Mechanism of Effect

Saffron stigma, petal and crocin are distinct research preparations. The clinical contribution of serotonin and GABA mechanisms in humans remains uncertain.

Clinical Evidence

A 2005 pilot trial in 40 adults with mild to moderate depression compared 30 mg/day of saffron stigma extract with 20 mg/day of fluoxetine for 6 weeks. Depression scores did not differ significantly between groups.

The 2013 meta-analysis included 2 placebo-controlled trials and 3 trials comparing saffron with antidepressants. Depression scores fell more with saffron in the placebo comparisons.

For PMS symptoms: In a randomized controlled study (Agha-Hosseini et al., 2008), it was reported that 30 mg/day saffron provided a significant reduction in PMS-related mood lability and irritability compared to placebo. Lopresti and Drummond (2014) is a systematic review compiling the effects of saffron on depression and its antidepressant mechanisms of action.

In a 2015 pilot trial, 40 people with major depression were randomized to 30 mg/day of crocin or placebo alongside an SSRI. At 4 weeks, self-reported depression scores fell more in the crocin arm.

The short pilot did not study SSRI-related sexual dysfunction. Its findings do not apply to all saffron extracts or establish the long-term safety of drug combinations.

Dose information and research limits

Many early saffron trials used 30 mg/day, but products, plant parts and standardization differ. Whole saffron, petals, crocin and proprietary extracts are not identical formulations or equivalent doses; these comparisons do not set a personal treatment dose.

Safety and Side Effects

The 2026 safety review included 102 clinical trials and 1 case report. Digestive symptoms were the most commonly reported adverse effects. Some trials did not report adverse effects.

Supplement safety data during pregnancy and breastfeeding are limited. These studies do not establish safety when combined with antidepressants or blood thinners.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Akhondzadeh S, et al. (2004). Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complementary and Alternative Medicine, 4, 12. PubMed · PMID 15341662
  2. Noorbala AA, Akhondzadeh S, et al. (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology, 97(2), 281–284. PubMed · PMID 15707766
  3. Hausenblas HA, et al. (2013). Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. Journal of Integrative Medicine, 11(6), 377–383. PubMed · PMID 24299602
  4. Lopresti AL, Drummond PD. (2014). Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human Psychopharmacology, 29(6), 517–527. PubMed · PMID 25384672
  5. Moshiri E, et al. (2006). Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine, 13(9–10), 607–611. PubMed · PMID 16979327
  6. Talaei A, et al. (2015). Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. Journal of Affective Disorders, 174, 51–6. https://doi.org/10.1016/j.jad.2014.11.035 PubMed · PMID 25484177
  7. Agha-Hosseini M, et al. (2008). Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG, 115(4), 515–9. https://doi.org/10.1111/j.1471-0528.2007.01652.x PubMed · PMID 18271889
  8. Hasheminasab FS, Hajimonfarednejad M, Najibi SM, Hashempur MH. (2026). Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence. Health Science Reports, 9(5), e72212. PubMed · PMID 42057871

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions